Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02299921

Effect of Alcohol and Drugs of Abuse on Immune Function in Critically Ill Patients With Respiratory Failure

This study plans to learn more about people who are sick in the hospital with a lung infection, or respiratory failure. Respiratory failure, or severe lung failure, is a life-threatening disease. When it happens, the lungs have trouble carrying out their normal function of getting oxygen into the blood, and removing carbon dioxide from the body. Investigators are conducting this study to see what drinking too much alcohol, using tobacco products, or using drugs (both legal and illegal) may do to lung infections and respiratory failure.

Subjects are asked to be in this research study because they are thought to have a lung infection and may also have respiratory failure. Alcohol, tobacco, and drug use have been linked to lung infections, respiratory failure, and even death, but the reasons for this aren't known. People who use unhealthy amounts of alcohol, tobacco, and or drugs may be more at risk for lung infections, and for severe complications due to lung infection. Subject participation is important whether or not you use alcohol and or drugs.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Infection Alcohol Abuse Alcohol-Related Disorders Alcoholism Chemically-Induced Disorders Drugs of Abuse Infections Lung Diseases Lung Injury Mental Disorders Respiratory Tract Diseases Substance-Related Disorders Thoracic Injuries Wounds and Injuries

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Specific Aim 1: Adult medical ICU patients admitted to the University of Colorado Hospital for a primary respiratory problem, and who are expected to require ICU care ≥48 hrs
  • Specific Aim 2: (1) Adult medical ICU patients with respiratory failure (due to underlying lung pathology) and who require endotracheal intubation and mechanical ventilation. (2) Adult medical and other ICU patients with respiratory failure, not related to a lung condition, and who require endotracheal intubation and mechanical ventilation. (3) Adult ICU patients previously admitted to the University of Colorado Hospital for a primary respiratory problem, and who required care ≥48 hrs.

Exclusion criteria

, Specific Aim 1 and 2:

  • Patients who are expected to require ICU care <48 hrs
  • Patients admitted to the ICU who are not ICU status (being housed for space issues)
  • Patient is unlikely to survive 48 hours
  • Patient is on comfort care (hospice measures)
  • Patients less than 18 or greater than 90 years of age
  • Patient is a prisoner
  • ICU attending declines enrollment of patient
  • Patients who are pregnant
  • Patients who have significant anemia, defined as Hgb<8% or Hct<24%, or who have evidence of active bleeding.

For bronchoscopy portion of Specific Aim 2.

  • Patients who are on either a fraction of inspired oxygen inspired oxygen fraction (FiO2)>80% or positive end expiratory pressure (PEEP) >10 cm H20
  • Patients with platelets less than 30,000(chronically)
  • Patients who are expected to undergo a spontaneous breathing trial within the next 4 hours
  • Patients with an order or plan to extubate in the next 4 hours
  • Patients who have an endotracheal tube (ETT) <7.5 F
  • Patients who are currently dangerously agitated
  • Pregnant women

Exclusion criteria

(outpatients ONLY for SA2 (3)):

  • Patients who required ICU care <48 hrs
  • Patients less than 18 or greater than 90 years of age
  • Patient is a prisoner
  • Patients who are pregnant
  • Residency > 40 miles from UCH clinics
  • non-English or non-Spanish speaking
  • Inability to perform study procedures (i.e. physical disability)
  • unable to perform pulmonary function testing
  • diagnosis of chronic pulmonary disease (e.g. COPD)
  • diagnosis of chronic neurodegenerative disease or severe dementia
  • history of anoxic or traumatic brain injury
  • prior ICU hospitalization at a non-UCH facility.

Treatment and study plan

Characterize alcohol and drug use

Other

Characterize alcohol and drug use in patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. The investigators will collect blood, exhaled breath condensate, urine and hair samples over the first 10 days of hospitalization. A select subset of subjects will have bronchoalveolar lavage (BAL) obtained.

Primary outcomes

  1. Prevalence of alcohol use disorders (AUDs)

    Time frame: prevalence, absolute value and change over 7 days, 3 Month follow up, 6 Month follow up

    Among medical ICU (MICU) patients who remain in ICU greater than or equal to 48 hours: Prevalence of alcohol use disorders (AUDs), drug use disorders (DUDs), their combination (both), or no AUD/DUDs. Absolute value, and change over 7 days, in serum/urine/exhaled breath condensate/hair cortisol, corticotropin releasing hormone (CRH), adenovirus proteinase (AVP), and adrenocorticotropic hormone (ACTH), stratified by AUD/DUD/both/neither. 3 Month and 6 Month follow up were added to this outcome measure via a protocol amendment after study-start.

  2. Incidence and etiology of respiratory failure, stratified by AUD/DUD/both/neither

    Time frame: participants will be followed for the duration of hospital stay, an expected average of 17 days

    Among medical ICU (MICU) patients who develop respiratory failure: Incidence and etiology of respiratory failure, stratified by AUD/DUD/both/neither. Length of time on mechanical ventilation stratified by AUD/DUD/both/neither. Inflammatory profile of BAL stratified by AUD/DUD/both/neither: BAL cell count and differential, Pro-inflammatory BAL cytokines; CCL5, TNFa, interferon-gamma (IFNg), interleukin (IL-1b), interleukin (IL-6). Evidence of oxidative stress in BAL (GSH/glutathione disulfide (GSSG) ratio, pH). Alveolar macrophage activation, degree of apoptosis, and inflammatory cytokine production. Confirm in non-invasively collected samples. Development of Acute Respiratory Distress Syndrome (ARDS) stratified by AUD/DUD/both/neither; Berlin criteria, Lung injury score.

  3. Incidence and etiology of respiratory failure, stratified by AUD/DUD/both/neither: Month 3

    Time frame: 3 Month follow up

    Among medical ICU (MICU) patients who develop respiratory failure: Incidence and etiology of respiratory failure, stratified by AUD/DUD/both/neither. Length of time on mechanical ventilation stratified by AUD/DUD/both/neither. Inflammatory profile of BAL stratified by AUD/DUD/both/neither: BAL cell count and differential, Pro-inflammatory BAL cytokines; CCL5, TNFa, interferon-gamma (IFNg), interleukin (IL-1b), interleukin (IL-6). Evidence of oxidative stress in BAL (GSH/glutathione disulfide (GSSG) ratio, pH). Alveolar macrophage activation, degree of apoptosis, and inflammatory cytokine production. Confirm in non-invasively collected samples. Development of Acute Respiratory Distress Syndrome (ARDS) stratified by AUD/DUD/both/neither; Berlin criteria, Lung injury score. 3 Month and 6 Month follow up were added to this outcome measure via a protocol amendment after study-start.

  4. Incidence and etiology of respiratory failure, stratified by AUD/DUD/both/neither: Month 6

    Time frame: 6 Month follow up

    Among medical ICU (MICU) patients who develop respiratory failure: Incidence and etiology of respiratory failure, stratified by AUD/DUD/both/neither. Length of time on mechanical ventilation stratified by AUD/DUD/both/neither. Inflammatory profile of BAL stratified by AUD/DUD/both/neither: BAL cell count and differential, Pro-inflammatory BAL cytokines; CCL5, TNFa, interferon-gamma (IFNg), interleukin (IL-1b), interleukin (IL-6). Evidence of oxidative stress in BAL (GSH/glutathione disulfide (GSSG) ratio, pH). Alveolar macrophage activation, degree of apoptosis, and inflammatory cytokine production. Confirm in non-invasively collected samples. Development of Acute Respiratory Distress Syndrome (ARDS) stratified by AUD/DUD/both/neither; Berlin criteria, Lung injury score. 3 Month and 6 Month follow up were added to this outcome measure via a protocol amendment after study-start.

Study contacts

Contact information is provided by the study sponsor or research team.

Ellen L Burnham, MD

CONTACT

[email protected]

303-724-6078

Sponsors and collaborators

Lead sponsor

University of Colorado, Denver

Other

Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Registry information

Important dates

Study start
2014
Primary completion
2029
Study completion
2029
First posted
Nov 24, 2014
Registry last updated
Oct 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.